contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


integrum-ab-integrum-ce-marks-neuromotustm-a-novel-system-for-phantom-limb-pain-treatment

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Integrum is active in medical technology. The company develops systems for skeletally anchored prostheses based on the developed OPRA implant system, which is later resold to hospitals worldwide. The implant is placed on the patient's leg with the help of titanium screws and is believed to improve the lives of a large number of patients with amputation. The company was founded in 1998 and has its headquarters in Mölndal.

Integrum

Phantom limb pain (PLP) is a deteriorating condition for which there has been no effective treatment. The prevalence of PLP among amputees is reported to be between 42-80%. Patients suffering...

Phantom limb pain (PLP) is a deteriorating condition for which there has been no effective treatment. The prevalence of PLP among amputees is reported to be between 42-80%. Patients suffering from PLP have historically been neglected, mostly because of the lack of an effective treatment, and the poor understanding of the condition. These patients are often left to be permanently medicated with the all the downsides of using strong pain killers or resigned to a life with chronic pain.Neuromotus™ provides a solution for people suffering phantom limb pain. A recently published study in the Lancet (the top ranked European scientific journal) showed that our product is an effective option even for patients where all other treatments have failed. Patients who had suffered of chronic phantom limb pain for decades without any effective treatment option were relieved from their constant pain and reduced their dependency on pain medications after using our product. These improvements were still observable 6 months after treatment which is of great importance for the clinical relevance for treatments of chronic conditions.Integrum is currently present at the health care conference, Vitalis 2019, held 21-23rd May 2019 at Svenska Mässan, Gothenburg, to demonstrate the system. Dr. Max Ortiz Catalan will speak about the scientific background and clinical findings with this technology in the same conference on 22nd May at 2 pm." Neuromotus™ echoes with Integrum's commitment to improving life for people with amputation. We are glad to know that our product can help people around the world suffering from phantom limb pain and will enable them to have a better life. I am happy to see that we already have orders from several clinics and research centers in Europe", says María López, CEO at Integrum.   For further information contactMaría López, CEO. Cell: +46 708 46 10 69, <virtloc>Email: maria.lopez@integrum.se</virtloc>This information is such that Integrum AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 8.00 CET on May 21, 2019.Integrum AB is listed on Nasdaq First North in Stockholm. Erik Penser Bank is the Company's Certified AdviserCertified AdviserErik Penser Bank AB, Certified Adviser can be reached at +46 8 463 8000 or <virtloc>certifiedadviser@penser.se</virtloc>

Integrum AB: Integrum CE marks Neuromotus™ - a novel system for phantom limb pain treatment